Back to News
Market Impact: 0.56
Telix to Buy Isotope Maker ITM in Deal Worth Up to $2.35 Billion
Source: Bloomberg
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Telix Pharmaceuticals agreed to acquire ITM Isotope Technologies Munich for up to $2.35 billion. The transaction secures a key supply source of radioactive materials used in cancer therapies and adds a late-stage drug candidate, strengthening Telix's radiopharmaceutical pipeline and vertical integration.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
TLX0.72
More News
- Why is Telix Pharmaceuticals stock sliding today?
- Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
- China slows humanoid robot IPO rush as hype outruns reality
- Porsche could face another 4,000 job cuts, Handelsblatt reports
- SoftBank plans more than $11 bln bond sale to fund OpenAI bets, Bloomberg reports